Latest News and Press Releases

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.

Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.

Longeveron issues letter to shareholders highlighting corporate strategy, recent progress and 2025 key priorities and goals.

Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.

Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.

Longeveron to present at the Roth investor conference taking place March 17-18, 2025. Company fireside chat Tuesday, March 18th at 9:00am PT.

Longeveron announces 2024 financial results and provides business update. Pivotal Phase 2b clinical trial achieves 90% enrollment.

Longeveron to report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close.

WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS.